Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191,293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.
Ravindranathan S, Passang T, Li JM, Wang S, Dhamsania R, Ware MB, Zaidi MY, Zhu J, Cardenas M, Liu Y, Gumber S, Robinson B, Sen-Majumdar A, Zhang H, Chandrakasan S, Kissick H, Frey AB, Thomas SN, El-Rayes BF, Lesinski GB, Waller EK. Ravindranathan S, et al. Among authors: liu y. Nat Commun. 2022 Oct 27;13(1):6418. doi: 10.1038/s41467-022-34242-4. Nat Commun. 2022. PMID: 36302761 Free PMC article.
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer.
Ruggieri AN, Yarchoan M, Goyal S, Liu Y, Sharon E, Chen HX, Olson BM, Paulos CM, El-Rayes BF, Maithel SK, Azad NS, Lesinski GB. Ruggieri AN, et al. Among authors: liu y. Clin Cancer Res. 2022 Oct 3;28(19):4336-4345. doi: 10.1158/1078-0432.CCR-22-1123. Clin Cancer Res. 2022. PMID: 35833954 Free PMC article. Clinical Trial.
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sanda GE, Shabto JM, Goyal S, Liu Y, Martini DJ, Nazha B, Brown JT, Yantorni LB, Anne Russler G, Caulfield S, Joshi SS, Narayan VM, Kissick H, Ogan K, Master VA, Carthon BC, Kucuk O, Bilen MA. Sanda GE, et al. Among authors: liu y. Oncologist. 2023 Dec 11;28(12):1072-1078. doi: 10.1093/oncolo/oyad154. Oncologist. 2023. PMID: 37285524 Free PMC article.
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Saba NF, Steuer CE, Ekpenyong A, McCook-Veal A, Magliocca K, Patel M, Schmitt NC, Stokes W, Bates JE, Rudra S, Remick J, McDonald M, Abousaud M, Tan AC, Fadlullah MZH, Chaudhary R, Muzaffar J, Kirtane K, Liu Y, Chen GZ, Shin DM, Teng Y, Chung CH. Saba NF, et al. Among authors: liu y. Nat Med. 2023 Apr;29(4):880-887. doi: 10.1038/s41591-023-02275-x. Epub 2023 Apr 3. Nat Med. 2023. PMID: 37012550 Free PMC article. Clinical Trial.
Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy.
Sebastian N, Goyal S, Liu Y, Janopaul-Naylor JR, Patel PR, Dhere VR, Hanasoge S, Shelton JW, Godette KD, Jani AB, Hershatter B, Fischer-Valuck B, Patel SA. Sebastian N, et al. Among authors: liu y. JAMA Netw Open. 2023 Aug 1;6(8):e2327637. doi: 10.1001/jamanetworkopen.2023.27637. JAMA Netw Open. 2023. PMID: 37552479 Free PMC article.
191,293 results
You have reached the last available page of results. Please see the User Guide for more information.